ZA200608884B - Methods of treating autoimmune and inflammatory diseases - Google Patents

Methods of treating autoimmune and inflammatory diseases Download PDF

Info

Publication number
ZA200608884B
ZA200608884B ZA200608884A ZA200608884A ZA200608884B ZA 200608884 B ZA200608884 B ZA 200608884B ZA 200608884 A ZA200608884 A ZA 200608884A ZA 200608884 A ZA200608884 A ZA 200608884A ZA 200608884 B ZA200608884 B ZA 200608884B
Authority
ZA
South Africa
Prior art keywords
inflammatory
antibody
tissue
medicament
monoclonal antibody
Prior art date
Application number
ZA200608884A
Other languages
English (en)
Inventor
Mach Bernard
Kosco-Vilbois Marie
Dean Yann
Original Assignee
Novimmune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novimmune Sa filed Critical Novimmune Sa
Publication of ZA200608884B publication Critical patent/ZA200608884B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA200608884A 2004-04-06 2006-10-25 Methods of treating autoimmune and inflammatory diseases ZA200608884B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06

Publications (1)

Publication Number Publication Date
ZA200608884B true ZA200608884B (en) 2008-06-25

Family

ID=35150504

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608884A ZA200608884B (en) 2004-04-06 2006-10-25 Methods of treating autoimmune and inflammatory diseases

Country Status (19)

Country Link
US (1) US20050265993A1 (de)
EP (1) EP1737490B1 (de)
JP (1) JP4812748B2 (de)
KR (1) KR20070036035A (de)
CN (2) CN102847149B (de)
AT (1) ATE470453T1 (de)
AU (1) AU2005232653B2 (de)
CA (1) CA2563260C (de)
DE (1) DE602005021766D1 (de)
DK (1) DK1737490T3 (de)
EA (1) EA012725B1 (de)
ES (1) ES2348984T3 (de)
IL (2) IL178478A (de)
MX (1) MXPA06011526A (de)
NO (2) NO340627B1 (de)
PT (1) PT1737490E (de)
UA (2) UA89780C2 (de)
WO (1) WO2005099755A2 (de)
ZA (1) ZA200608884B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
SG10201808730VA (en) † 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
WO2011147767A1 (en) * 2010-05-24 2011-12-01 Indena S.P.A. Tamarind seed polysaccharide for use in the treatment of microbial infections
US20130273055A1 (en) * 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
AU2019242912B2 (en) 2018-03-28 2025-07-17 Board Of Regents, The University Of Texas System Identification of epigenetic alterations in DNA isolated from exosomes
CN113507935A (zh) * 2018-10-16 2021-10-15 得克萨斯州大学系统董事会 用于诊断和治疗癌症及其他疾病的对致病性胞外基质的鉴定和靶向
US20220008533A1 (en) * 2018-10-31 2022-01-13 Tiziana Life Sciences Plc Composition and methods of treating inflammatory and autoimmune diseases
EP4493592A1 (de) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispezifische gpc3xcd28- und gpc3xcd3-antikörper und deren kombination zur gezielten tötung gpc3-positiver maligner zellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
WO1994026303A1 (en) * 1993-05-13 1994-11-24 Neorx Corporation Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
CN1953767B (zh) * 2004-01-08 2011-03-16 加利福尼亚大学董事会 调节t细胞抑制自身免疫

Also Published As

Publication number Publication date
KR20070036035A (ko) 2007-04-02
JP2007532565A (ja) 2007-11-15
DK1737490T3 (da) 2010-10-04
NO20170737A1 (no) 2006-11-06
CA2563260C (en) 2013-05-28
JP4812748B2 (ja) 2011-11-09
CA2563260A1 (en) 2005-10-27
IL178478A (en) 2010-12-30
WO2005099755A3 (en) 2006-04-27
HK1099525A1 (en) 2007-08-17
NO340627B1 (no) 2017-05-15
CN102847149B (zh) 2016-01-20
MXPA06011526A (es) 2007-03-21
PT1737490E (pt) 2010-08-31
UA89780C2 (ru) 2010-03-10
WO2005099755A2 (en) 2005-10-27
DE602005021766D1 (de) 2010-07-22
NO20064896L (no) 2006-11-06
CN1972714B (zh) 2012-10-03
EP1737490A2 (de) 2007-01-03
EA012725B1 (ru) 2009-12-30
AU2005232653A1 (en) 2005-10-27
AU2005232653B2 (en) 2010-12-16
EP1737490B1 (de) 2010-06-09
CN1972714A (zh) 2007-05-30
UA103594C2 (ru) 2013-11-11
IL209338A0 (en) 2011-01-31
IL178478A0 (en) 2007-02-11
EA200601871A1 (ru) 2007-04-27
ATE470453T1 (de) 2010-06-15
US20050265993A1 (en) 2005-12-01
CN102847149A (zh) 2013-01-02
ES2348984T3 (es) 2010-12-21

Similar Documents

Publication Publication Date Title
US20240376210A1 (en) Vedolizumab for the treatment of fistulizing crohn's disease
NO20170737A1 (no) Anvendelse av anti-CD3 antistoff for fremstilling av et medikament mot aterosklerose, samt et anti-CD3 antistoff
JP6278224B2 (ja) Ｐｄ−１アゴニストからなる自己免疫疾患治療剤
UA124269C2 (uk) Застосування антагоністу il-13 для лікування атопічного дерматиту
CN114642661A (zh) 用于降低心血管风险的方法
CA2676185C (en) Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
EP1987066B1 (de) Verfahren zur behandlung von demyelinierenden krankheiten
CN114630681A (zh) 包含actrii受体拮抗剂的肝疾病或障碍的治疗
EP3641802B1 (de) Verfahren und pharmazeutische zusammensetzungen zur behandlung von fibrose mit mitteln zur hemmung der aktivierung von mukosa-assoziierten invarianten t-zellen (mait)
JP6430082B1 (ja) 低用量抗ｃｃｒ４抗体を用いたｈｔｌｖ−１関連脊髄症の予防または治療剤
CN111741768A (zh) 治疗IgE介导的过敏性疾病
JP2023506732A (ja) ホモ接合型家族性高コレステロール血症を処置するためのｐｃｓｋ９阻害剤の使用
HK1099525B (en) Methods of treating atherosclerosis
Ther Intravenous immune globulin suppresses angiogenesis in mice and humans